Heikki Lanckriet became the CEO of Expedeon AG (ETR:EXNN) in 2017. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll ...

Heikki Lanckriet became the CEO of Expedeon AG (ETR:EXNN) in 2017. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look ...

Abcam has completed the acquisition of Expedeon's proteomics and immunology business, which includes Innova and TGR Biosciences. Abcam and Expedeon said they were committed to providing continued ...

- Includes leading protein conjugation technologies and industry brands Lightning-Link and CaptSure - Opportunity to combine Expedeon and Abcam's technologies to create new products to support ...

- Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development CAMBRIDGE, England, Jan. 6, 2020 /PRNewswire/ -- Abcam plc, a ...

CAMBRIDGE, England, Jan. 6, 2020 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's ...

(Alliance News) - Abcam PLC said Thursday the completed purchase of Expedeon AG's proteomics and immunology businesses for EUR120 million positions Abcam well for growth. Alan Hirzel, chief ...

Expedeon shareholders have approved the sale of its proteomics and immunology business, as well as the proposed name change to 4basebio AG, reflecting the Company’s future focus on DNA manufacturing ...

DGAP-News: Expedeon AG / Key word(s): Contract11.11.2019 / 08:31 The issuer is solely responsible for the content of this announcement.PRESS RELEASE11 November 2019 Expedeon AG signs EUR 120 million ...

Expedeon AG / Key word(s): Disposal Expedeon AG: Expedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomics business 11-Nov-2019 / 08:29 CET/CEST Disclosure of an ...